|
|
|
|
|
|
|
|
Algernon NeuroScience Reports Successful Second Cohort Dosing in DMT Clinical Study
|
Vancouver, BC, May 3, 2023--Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, announced tioday that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 ("N,N-Dimethyltryptamine" or "DMT").
|
|
|
|
|
|
|